Based on some retrospective studies, the discordance rates of ER, PR, and HER2 exhibited considerable variation among breast cancer patients, ranging from 3% to 54% for ER, 5% to 78% for PR, and 0% to 34% for HER2 [19,20,21,22]. This evidence concerns the gene ERBB2 and breast carcinoma.